|
◇Psomagen Hits Record Revenue with Reconstructed Financial Health
According to KG Zeroin MP DOCTOR on the 1st, genomics analysis specialist Psomagen saw its stock price surge by 18.21% from the previous trading day, closing at 3,310 won and placing it at the top of the biotech sector’s gainers on the Kosdaq market.
Market analysts attribute this sharp rally to a combination of a structural turnaround from chronic losses and decisive corporate actions to clean up its balance sheet. Psomagen recorded an all-time high consolidated revenue of 59.2 billion won last year, marking a staggering 35.5% growth compared to the previous year (43.7 billion won). Over the same period, its consolidated operating loss was slashed by more than half, narrowing from 5.2 billion won to 2.2 billion won. On a separate (non-consolidated) basis, excluding subsidiaries, the company achieved its first-ever annual operating profit since its founding, successfully restoring market confidence.
The primary catalyst for the stock’s momentum was the board’s announcement on April 30 to reduce its capital surplus by $75 million (approx. 116.6 billion won) to completely wipe out its accumulated deficit of $61.33 million (approx. 95.4 billion won). This accounting adjustment erases the legacy deficit on paper, establishing a clean slate to accumulate future earnings entirely as retained earnings. The company clarified that this is a reclassification between equity accounts and does not alter its actual total equity or the number of outstanding shares.
A robust order backlog further supports the stock's upward trajectory. Psomagen continues to secure Next-Generation Sequencing (NGS) projects from major global partners, including U.S. government agencies and the Michael J. Fox Foundation. Additionally, its direct-to-consumer (DTC) genetic testing revenue, primarily driven by the Japanese market, more than doubled year-over-year.
Furthermore, the company recently obtained a molecular genetics testing clinical laboratory certification from the New York State Department of Health, granting it access to North America’s largest regional market. With the anticipated tailwinds from the U.S. Biosecure Act—which looks to exclude Chinese competitors—the company is green-lit to achieve its mid-to-long-term revenue milestone of 100 billion won.
"Following our turn to profitability on a separate basis last year, this deficit cancellation has significantly elevated our financial soundness," said Ryan W. Kim (Hong-soo), CEO of Psomagen. "Moving forward, we will consistently build up our retained earnings through robust operational execution."
|
◇GFC Life Science Accelerates B2C Shift and Global Channels
Bio-material specialist GFC Life Science also caught investor attention, finishing the day up 12.09% at 5,470 won. The company's growth engine lies in its successful business model transformation, shifting from a business-to-business (B2B) focus to the high-margin business-to-consumer (B2C) market.
In March, the company officially entered the beauty market by launching "fmk," a high-performance derma-skincare brand powered by its proprietary bio-ingredient technologies. The brand aggressively targets the ingredient-conscious consumer trend with high-potency, high-efficacy products. Its flagship line includes an elasticity kit containing 500,000 ppm of salmon-derived Polydeoxyribonucleotide (PDRN) and a brightening kit infused with Vitamin C and Nicotinamide Mononucleotide (NMN).
To maximize the freshness and delivery of active ingredients, GFC Life Science introduced a freeze-drying method typically utilized in professional skin booster treatments. The company also secured a competitive edge by scientifically validating the skin-absorption mechanisms of its patented plant-derived exosomes (extracted from camellia, Houttuynia cordata, and lavender). Starting with its official online mall, fmk has rapidly expanded its footprint by launching on major Gen Z-favored platforms such as KakaoTalk Store, Ably, and Zigzag. For offline distribution, it has diversified consumer touchpoints by securing a supply network with "Korea Pharmacy," a major domestic pharmacy chain.
This aggressive B2C push is translating directly into financial results. GFC Life Science reported a first-quarter revenue of 5.04 billion won and an operating profit of 460 million won, representing a year-over-year increase of 12.2% and 16.7%, respectively. Net profit surged 59.9% to 480 million won, proving a definitive growth trajectory.
Looking ahead, the company plans to diversify its portfolio into a comprehensive derma brand by adding pore-care and skin-calming lines. At the same time, it is leveraging compliance with the Modernization of Cosmetics Regulation Act (MoCRA) in the U.S. and the Cosmetic Products Notification Portal (CPNP) in Europe to accelerate its global B2C expansion via Amazon and TikTok Shop, which is expected to drive further enterprise value.
"We will aggressively promote our freeze-dried kit line through these new products and lay the groundwork for global market expansion," a GFC Life Science official stated. "By strengthening both our B2B materials business and B2C brand operations, we will continue to diversify our revenue stream."
|
◇Jetema Eyeballs Chinese Toxin Approval and U.S. Skin Booster Entry
Medical aesthetics specialist Jetema joined the double-digit rally, closing up 10.57% at 5,490 won.
Jetema’s strength was driven by the simultaneous materialization of major milestones targeting China and the United States—the world’s largest aesthetic markets. In May, Jetema received approval for the Clinical Study Report (CSR) of its Phase 3 trial for 'JTM201', its botulinum toxin candidate, in China. The study demonstrated non-inferiority in improving glabellar (frown) lines and an identical safety profile compared to the original control group.
Based on these results, Jetema has finalized its roadmap to file a Biologics License Application (BLA) with the National Medical Products Administration (NMPA) of China, aiming for an official commercial launch in the second half of 2027. The company has already locked in a 10-year supply agreement worth 555 billion won with "Huadong Aesthetics," a distributor boasting a powerful local network. This secures a minimum guaranteed exclusive revenue of 55 billion won annually upon launch.
Concurrently, Jetema's strategic approach to the U.S. market boosted investor sentiment. Instead of waiting several years for a brand-new filler or toxin approval, Jetema plans to break into the U.S. skin booster (hydro-injection) market in the third quarter of this year. It will combine its non-crosslinked hyaluronic acid (HA) asset—which already holds a U.S. regulatory framework for osteoarthritis treatment—with an automated multi-needle injector that boasts a U.S. FDA clearance track record.
While the U.S. commands half of the global aesthetics market, institutional skin booster penetration remains practically non-existent. Jetema’s early-mover strategy centers on pre-empting local medical spa networks and hospital channels using this pre-verified infrastructure, later tying in its broader product portfolio.
On top of this, the company has equipped itself with a new growth engine in the ophthalmic treatment sector. Jetema recently announced plans to seek regulatory approval from the Ministry of Food and Drug Safety (MFDS) within the year for its presbyopia-improving eye drops, which recently completed Phase 3 trials in South Korea. The product maintains near-vision improvement efficacy for approximately six hours post-administration.
"We intend to expand our existing product portfolio from medical aesthetics into the broader well-aging healthcare sector," a Jetema official remarked. "We aim to secure an early foothold in the presbyopia treatment market leveraging our differentiated competitiveness."
Copyright ⓒ 이데일리 무단 전재 및 재배포 금지
본 콘텐츠는 뉴스픽 파트너스에서 공유된 콘텐츠입니다.
다음 내용이 궁금하다면?
광고 보고 계속 읽기
원치 않을 경우 뒤로가기를 눌러주세요
